Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Aug 28, 16:00
Kezar Life Sciences Cash from Operations (Quarterly) : -7.445M for March 31, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -7.445M |
| December 31, 2025 | -11.96M |
| September 30, 2025 | -9.83M |
| June 30, 2025 | -12.80M |
| March 31, 2025 | -17.19M |
| December 31, 2024 | -16.82M |
| September 30, 2024 | -17.49M |
| June 30, 2024 | -17.03M |
| March 31, 2024 | -22.86M |
| December 31, 2023 | -18.98M |
| September 30, 2023 | -20.20M |
| June 30, 2023 | -21.60M |
| March 31, 2023 | -20.86M |
| December 31, 2022 | -15.88M |
| September 30, 2022 | -16.36M |
| June 30, 2022 | -13.29M |
| March 31, 2022 | -13.31M |
| December 31, 2021 | -11.08M |
| September 30, 2021 | -9.954M |
| Date | Value |
|---|---|
| June 30, 2021 | -13.04M |
| March 31, 2021 | -8.357M |
| December 31, 2020 | -9.307M |
| September 30, 2020 | -9.25M |
| June 30, 2020 | -10.09M |
| March 31, 2020 | -8.301M |
| December 31, 2019 | -7.21M |
| September 30, 2019 | -8.255M |
| June 30, 2019 | -7.712M |
| March 31, 2019 | -6.70M |
| December 31, 2018 | -5.473M |
| September 30, 2018 | -4.604M |
| June 30, 2018 | -6.949M |
| March 31, 2018 | -3.766M |
| December 31, 2017 | -1.616M |
| September 30, 2017 | -2.178M |
| June 30, 2017 | -2.303M |
| March 31, 2017 | -2.012M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0336M |
| Brainstorm Cell Therapeutics, Inc. | -0.895M |
| Summit Therapeutics, Inc. | -140.55M |
| Protara Therapeutics, Inc. | -15.39M |
| Clene, Inc. | -2.578M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 1.529M |
| Cash from Financing (Quarterly) | 0.267M |
| Free Cash Flow | -42.03M |
| Free Cash Flow Per Share (Quarterly) | -1.014 |
| Free Cash Flow to Equity (Quarterly) | -6.473M |
| Free Cash Flow to Firm (Quarterly) | -7.445M |
| Free Cash Flow Yield | -78.70% |